+499.5%
MRNA vs CHTR
-41.9%
+541.4%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | CHTR | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | +0.4% | -2.6% | -2.3% |
| 7D | +5.5% | -1.1% | +6.5% | +5.5% |
| 30D | +158.7% | -0.8% | +159.5% | +158.6% |
| 3M | +182.1% | +17.8% | +164.4% | +176.6% |
| 6M | +151.8% | -34.5% | +186.3% | +164.4% |
| YTD | +393.6% | -27.2% | +420.7% | +412.1% |
| 1Y | +499.5% | -41.4% | +540.9% | +514.2% |
| All | +499.5% | -41.9% | +541.4% | +514.2% |
Cumulative growth
Daily Returns
Daily percentage return beside CHTR.
Daily Out/Under-Performance
Portfolio return minus CHTR return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × CHTR return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded CHTR wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling